Role of Lacosamide in Preventing Pentylenetetrazole Kindling-Induced Alterations in the Expression of the Gamma-2 Subunit of the GABAA Receptor in Rats
- 9 July 2020
- journal article
- research article
- Published by Elsevier in Current Molecular Pharmacology
- Vol. 13 (3) , 251-260
Abstract
Background: Epilepsy remains challenging to treat still no etiologic treatment has been identified, however, some antiepileptic drugs (AEDs) are able to modify the pathogenesis of the disease. Lacosamide (LCM) has been shown to possess complex anticonvulsant and neuroprotective actions, being an enhancer of the slow inactivation of voltage-gated sodium channels, and it has the potential to prevent epileptogenesis. Recent evidence has shown that LCM indirectly improves the function of GABAA receptors. Receptors at most GABAergic synapses involve the gamma-2 subunit, which contributes to both phasic and tonic inhibition, and its presence assures benzodiazepine sensitivity. Moreover, mutant gamma-2 subunits were associated with generalized epilepsy syndromes. In animal models, the expression of the gamma-2 subunit of the gamma-aminobutyric acid A receptor (GABAAg2) was shown to be increased in pentylenetetrazole (PTZ)-induced chemical kindling in Wistar rats. Objective: This study hypothesized that LCM might affect the kindling process by influencing the expression of GABAA receptors in the hippocampus. Methods: The gene and protein expression levels of the GABAAg2 were studied using RT-qPCR and immunofluorescent staining. Results: It was found that LCM treatment (10 mg/kg i.p. daily for 57 days) reduced the maximal intensity of the PTZ-induced seizures but did not prevent kindling. On the other hand, LCM treatment reverted the increase of mRNA expression of GABAAg2 in the hippocampus and prevented the decrease of GABAAg2 protein in the hippocampal CA1 region. Conclusion: LCM could exhibit modulatory effects on the GABAergic system of the hippocampus that may be independent of the anticonvulsant action.Keywords
Funding Information
- Studium Prospero Foundation and the Hungarian Academy of Sciences (137/26.01.2017)
This publication has 35 references indexed in Scilit:
- Lacosamide modulates interictal spiking and high-frequency oscillations in a model of mesial temporal lobe epilepsyEpilepsy Research, 2015
- Current understanding of the mechanism of action of the antiepileptic drug lacosamideEpilepsy Research, 2015
- Specific Binding of Lacosamide to Collapsin Response Mediator Protein 2 (CRMP2) and Direct Impairment of its Canonical Function: Implications for the Therapeutic Potential of LacosamideMolecular Neurobiology, 2014
- Lacosamide treatment following status epilepticus attenuates neuronal cell loss and alterations in hippocampal neurogenesis in a rat electrical status epilepticus modelEpilepsia, 2013
- Mechanisms of epileptogenesis: a convergence on neural circuit dysfunctionNature Reviews Neuroscience, 2013
- Modern antiepileptic drug development has failed to deliver: Ways out of the current dilemmaEpilepsia, 2011
- Strategies for antiepileptogenesis: Antiepileptic drugs versus target-specific approachesEpilepsia, 2010
- Therapeutic approaches to epileptogenesis—Hope on the horizonEpilepsia, 2010
- Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsyEpilepsy Research, 2007
- Effects of the Novel Antiepileptic Drug Lacosamide on the Development of Amygdala Kindling in RatsEpilepsia, 2006